JP
ENTL

John Paulson’s Entellus Medical, Inc. Common Stock ENTL Stock Holding History

John Paulson’s Portfolio ENTL Stock Details ENTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-102,702
Closed -$1.7M – 105
2017
Q2 		$1.7M Buy
+102,702
New +$1.43M 0.02% 95

Other funds holding ENTL

EWM
Essex Woodlands Management The Woodlands, Texas $254M AUM 4.59% 1-Year Est. Return
SHI
SV Health Investors Boston, Massachusetts $32.3M AUM 20.15% 1-Year Est. Return
DGI
Discovery Group I Chicago, Illinois $262M AUM 29.24% 1-Year Est. Return
KKRC
Kohlberg Kravis Roberts & Co New York $5.71B AUM 72.37% 1-Year Est. Return
FCM
Frontier Capital Management Boston, Massachusetts $10.7B AUM 67.78% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $2.4B AUM 42.85% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.65B AUM 203.21% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

John Paulson's ENTL Position: Q3 2017 in Review

John Paulson sold out of Entellus Medical, Inc. Common Stock (ENTL) in Q3 2017, closing a stake of 102,702 shares — an estimated $1.7M sold.

John Paulson first reported a position in ENTL in Q2 2017 and held it in 1 quarter. The position peaked at $1.7M in Q2 2017. 72 funds tracked by Wall St. Rank hold ENTL as of Q3 2017.

  • John Paulson reported no remaining Entellus Medical, Inc. Common Stock position as of Q3 2017 after selling out during the quarter.
  • John Paulson sold 102,702 Entellus Medical, Inc. Common Stock shares in Q3 2017, an estimated $1.7M.
  • John Paulson first reported a position in Entellus Medical, Inc. Common Stock in Q2 2017 and held it in 1 quarter.
  • John Paulson's Entellus Medical, Inc. Common Stock position peaked at $1.7M in Q2 2017.
  • 72 funds tracked by Wall St. Rank held Entellus Medical, Inc. Common Stock as of Q3 2017.

Based on Paulson & Co's 13F filing for Q3 2017, filed 14 Nov 2017.